Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis

Back

ESC Professional Premium Access

Semaglutide for the secondary prevention of cardiovascular disease in people with overweight or obesity, but without diabetes: a cost-effectiveness analysis

Session: Mapping cardiovascular health: risk factors, interventions, and geographic insights

Topic: Health Economics

Speaker: Associate Professor A. Nelson (Adelaide, AU)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Associate Professor Adam James Nelson

Royal Adelaide Hospital, Adelaide (Australia)

2 presentations

0 follower

4 more presentations in this session

Cardiovascular risk factors and disease mortality among asian american subgroups

Speaker: Doctor R. Aggarwal (Boston, US)

Mortality rate of percutaneous coronary interventions in st-segment elevation myocardial infarction patients under the public health insurance schemes of thailand

Speaker: Mr S. Chumsantivut (Bangkok, TH)

Air pollution and cerebrovascular diseases - retrospective analysis of 10,486 cases of acute ischemic stroke requiring intravenous thrombolysis. A report from the EP-PARTICLES study

Speaker: Mr M. Swieczkowski (Bialystok, PL)

Analyzing the economic ramifications of the broad implementation of generic prasugrel

Speaker: Doctor F. Gerardo (Amadora, PT)

Access the full session

Mapping cardiovascular health: risk factors, interventions, and geographic insights

Speakers: Associate Professor A. Nelson, Doctor R. Aggarwal, Mr S. Chumsantivut, Mr M. Swieczkowski, Doctor F. Gerardo

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources